Return to search results
Fezolinetant
VEOZAH (fezolinetant) is a prescription tablet by Astellas Pharma US, Inc., approved in May 2023. It works as a neurokinin 3 receptor antagonist to treat moderate to severe hot flashes in menopausal women. Taken orally at 45 mg once daily. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | VEOZAH (fezolinetant) is a prescription tablet by Astellas Pharma US, Inc., approved in May 2023. It works as a neurokinin 3 receptor antagonist to treat moderate to severe hot flashes in menopausal women. Taken orally at 45 mg once daily. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Fezolinetant",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Fezolinetant — ANDA 216578 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216578"
}
]
|
| identifier | ANDA216578 |
| issued | 2016-09-16 |
| keyword |
[
"drug-manufacturers",
"drug-safety",
"fda",
"prescription-drugs",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Fezolinetant |
